Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | POLA1 | P09884 | 1/20 | 0.30 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6602326 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRHPGDFAAH | |
| SCHEMBL30840393 | 0.79 | TSHR (0.33) | TSHR | |
| SCHEMBL6012107 | 0.77 | AKR1B1 (0.36) | ALDH1A1TSHRCES2CES1 | |
| SCHEMBL9848119 | 0.75 | TDP1 (0.35) | ALDH1A1TSHRCA1CA2FAAH | |
| SCHEMBL392932 | 0.74 | EPHX1 (0.30) | EPHX1 | |
| SCHEMBL7839516 | 0.73 | ALDH1A1 (0.35) | ALDH1A1TSHREPHX1CA1CA2 | |
| SCHEMBL9848101 | 0.72 | ALDH1A1 (0.39) | ALDH1A1CES2CES1 | |
| SCHEMBL907589 | 0.71 | ALDH1A1 (0.49) | ALDH1A1TSHR | |
| SCHEMBL16666931 | 0.71 | TSHR (0.52) | ALDH1A1TSHRCA2POLBPOLA1 | |
| Hexane SCHEMBL27951935 | 0.70 | ALDH1A1 (0.71) | ALDH1A1TSHREPHX1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027739-A | Preparation method of ink for automobile toughened glass | 浙江浦江永进工贸有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117858872-A | Heterocyclic EGFR inhibitors for the treatment of cancer | 缆图药品公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
| WO-2020123855-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2020-06-18 | — | — | WO | disclosed |
| US-9108957-B2 | 3-[1,4]oxazepane-4-pyrimidone derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-08-18 | — | — | US | disclosed |
| EP-2229942-B1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPE SPA (IT) | 2012-08-29 | — | — | EP | disclosed |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | SANOFI (FR) | 2012-04-19 | — | — | US | disclosed |
| EP-2414349-A1 | 3-Ý1,4¨OXAZEPANE-4-PYRIMIDONE DERIVATIVES | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| US-20030028021-A1 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2003-02-06 | — | — | US | disclosed |
| EP-1218359-A2 | PIPERAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001025219-A2 | PIPERAZINE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2001-04-12 | — | — | WO | disclosed |
| EP-0929524-A1 | PYRIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND THEIR USE FOR CONTROLLING ANIMAL PESTS AND HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1999-07-21 | — | — | EP | disclosed |
| EP-0745089-B1 | ANTIPARASITIC AGENTS | PFIZER LTD (GB) | 1998-12-09 | — | — | EP | disclosed |
| WO-1998012179-A1 | PYRIDINE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND THEIR USE FOR CONTROLLING ANIMAL PESTS AND HARMFUL FUNGI | BASF AKTIENGESELLSCHAFT (DE) | 1998-03-26 | — | — | WO | disclosed |
| US-5723488-A | Antiparasitic agents | PFIZER INC. (US) | 1998-03-03 | — | — | US | disclosed |
| EP-0745089-A1 | ANTIPARASITIC AGENTS | Pfizer Limited (GB) | 1996-12-04 | — | — | EP | disclosed |
| WO-1995022552-A1 | ANTIPARASITIC AGENTS | PFIZER LIMITED (GB) | 1995-08-24 | — | — | WO | disclosed |
| US-5352820-A | Expedient route to aryl propenoic esters | AMERICAN CYANAMID COMPANY | 1994-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | ALDH1A1 1/4885TSHR 4512/4885EPHX1 671/4885 |
| US-20030028021-A1 | Chemical compounds | TACR1, TACR2, TAC3 | ALDH1A1 2294/4885TSHR 1620/4885EPHX1 2383/4885 |
| US-20120095216-A1 | 3-[1,4]OXAZEPANE-4-PYRIMIDONE DERIVATIVES | PSEN1, MAPT, PSEN2 | ALDH1A1 1679/4885TSHR 2855/4885EPHX1 3476/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | ALDH1A1 1/4885TSHR 4512/4885EPHX1 671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.